David Holtzman, M.D.

Scientific Co-Founder

Dr. Holtzman is a Scientific Co-Founding Member of C2N Diagnostics. Dr. Holtzman is an international authority in the field of Alzheimer’s Disease. He is the Andrew B. and Gretchen P. Jones Professor of Neurology and Developmental Biology at Washington University School of Medicine (WUSM). He is also head of WUSM’s Department of Neurology, the Associate Director of the institution’s Alzheimer’s Disease Research Center, and Co-Director of the Hope Center for Protein Aggregation and Neurodegeneration. A major focus of Dr. Holtzman’s research is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS, particularly as these mechanisms may relate to Alzheimer’s disease and injury to the developing brain. Dr. Holtzman attended the Honors Program in Medical Education at Northwestern University receiving his B.S. (1983) and M.D. (1985). He completed his medical internship followed by Neurology residency at UCSF from 1985-1989. He then pursued post-doctoral research training in the lab of William C. Mobley, MD, PhD, at UCSF from 1989-1994. Also at UCSF, Dr. Holtzman established the Memory and Cognitive Disorders Clinic and was an Assistant Professor from 1991-1994. He moved to his own laboratory at WUSM in December of 1994. He was named as the Associate Professor of Neurology in 2001, Professor in November of 2002, and as the Andrew and Gretchen Jones Professor and Head of the Department of Neurology in October 2003. Dr. Holtzman is also involved in clinical and research activities at WUSM’s Alzheimer’s Disease Research Center. Past honors include recipient of a Paul Beeson Physician Faculty Scholar Award in Aging Research, the 2003 Potamkin Prize from the American Academy of Neurology for research on Alzheimer’s, election to the American Society for Clinical Investigation (2004), a MERIT award from the NIA (2004), and a 2006 recipient of the MetLife award on Alzheimer’s disease. In 2008, Dr. Holtzman was elected to the Institute of Medicine (IOM) of the National Academy of Sciences. He currently serves on the advisory council of the NINDS at the NIH.

Randall Bateman, M.D.

Scientific Co-Founder

Dr. Bateman is a Scientific Co-Founding Member of C2N Diagnostics. He is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine (WUSM). Dr. Bateman attended Case Western Reserve University School of Medicine, earning a medical degree with special emphasis on the neurosciences. He completed a Neurology residency at WUSM and then completed post-doctoral research training with David Holtzman, M.D., and clinical research fellowship training with John C. Morris, M.D. Dr. Bateman’s laboratory investigates the causes, and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques from basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers of Alzheimer’s disease. Dr. Bateman led the development of the SILK technique, which made it possible to determine that clearance of Ab is impaired in patients with Alzheimer’s disease. Bateman and his colleagues are now studying whether alterations in Ab clearance levels can be used to predict AD years before symptoms become apparent. Dr. Bateman is Associate Director and Clinical Core Leader of the Dominantly Inherited Alzheimer’s Network (DIAN), an international collaboration of leading research centers dedicated to studying autosomal dominant AD (ADAD). He is the Director of the DIAN Therapeutic Trials Unit (TTU), which is leading efforts to launch clinical trials in ADAD aiming to prevent the onset of memory impairment and dementia. Dr. Bateman’s honors include the Scientific American 50 Award, recognizing the top 50 scientific achievements of 2006; the St. Louis Academy of Science Innovator of the Year Award; a 2011 Alzheimer’s Association Zenith Fellows Award; and the 2012 MetLife Promising Investigator Award. He serves as an editor and reviewer for many prominent scientific journals and is a sought-after lecturer nationally and internationally.

Michael Goldblatt, Ph.D., J.D.

Dr. Goldblatt is an active investor in technology startups and consultant to a variety of government agencies, national laboratories and corporations. He brings over 35 years of experience in the areas of biotechnology, product development, and regulatory affairs to C2N. Michael was Chief Executive Officer of Functional Genetics, a biotechnology company focused on target discovery and antibody therapeutics, until 2013 when its assets were acquired by its collaboration partner Elanco. Michael joined Functional Genetics in 2003, after his appointment as Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA), and before that Dr. Goldblatt was the Science and Technology Officer for the McDonald’s Corporation with broad responsibilities, including nutrition, product development, food safety and corporate venture capital. Earlier, while at General Foods, he led research efforts in the use of nutrients for pharmaceutical effects and oversaw a variety of regulatory and legal issues. Michael holds dozens of active and pending US patents, and received his J.D. and Ph.D. from the University of California at Davis and a B.A. from Reed College.

Elizabeth John, Ph.D.

Dr. John has over 20 years of hands-on industry experience in the development of analytical methods, formulations, and processes for drugs and biologics. She has led the CMC development, quality control, and IND-filing of numerous therapeutic proteins and small molecules. Dr. John was VP of CMC Development at EnzymeRx (acquired by 3SBio), VP of Pharmaceutical Development / Regulatory Affairs at Proacta, Inc, Director of Pharmaceutical Development / Regulatory Affairs at Celmed BioSciences, and managerial roles at NewBiotics and NeoRx Corp.

Dee Athwal, Ph.D.

Dr. Athwal has extensive experience in the fields of novel antibody design, translational drug development, business development, and C-level operations in biopharmaceutical companies. Prior to his involvement with C2N, he was COO, CSO and CBO of Fourteen22, Inc, a biosimilars company, where he lead the operations and the raising of a $30M Series A financing round with TPG and 5AM Ventures. Prior to Fourteen22, he was a founding member of the management team and CSO, Head of Business Development at moksh8; VP, Business Development at UCB Celltech (1998-2007) and a Senior Principal Scientist at Celltech R+D for over 15 years. During that period, he was responsible for the design of humanized antibodies Celltech put into clinical development, including Mylotarg and Cimzia. Dr. Athwal is a visiting lecturer at several academic institutions in the UK and sits on a number of advisory Boards.